Overview

A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

Status:
Active, not recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
A trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
University of Liverpool
Collaborators:
AstraZeneca
Clinical Practice Research Datalink
Quintiles, Inc.
Treatments:
Dapagliflozin